Colin Dingwall

King's College London, United Kingdom

Colin Dingwall graduated with first-class honours in biochemistry from Newcastle University, UK. He then moved to the MRC Laboratory of Molecular Biology in Cambridge, UK, where he worked with Sir Alan Fersht FRS studying the proofreading mechanisms of the aminoacyl tRNA synthetases. He studied for his Ph.D. with Professor Ron Laskey FRS in the Cell Biology Division of the LMB. He was a Member at the Zoology Department at Cambridge from 1984 to 1988 and was elected Research Fellow at Clare Hall, Cambridge, UK, in 1986–1989. He discovered that nuclear protein transport is a signal-mediated, two-step process and identified the bipartite nuclear localisation signal (NLS) which is the major NLS in cellular proteins. He returned to the MRC LMB as a staff scientist to work on transactivation mechanisms in HIV gene regulation and discovered that the HIV regulatory protein Tat binds directly to HIV TAR RNA. From 1993–1995, he was a Visiting Scientist at EMBL, Heidelberg in the laboratory of Iain Mattaj as a Visiting Scientist working on snRNP transport. From there he moved to the State University of New York at Stony Brook, NY, USA, as a faculty member in the Pharmacology Department. In 1998, he was appointed Assistant Director in the Department of Neuroscience at SmithKline Beecham which became GlaxoSmithKline in 2001. Here he was involved in a number of drug discovery programmes directed toward the identification of a therapeutic for Alzheimer's disease and other neurodegenerative conditions. In particular, he was Biology Leader for the ?-secretase (BACE1) inhibitor programme, a key aspartic protease in the amyloidogenic pathway. In 2006, he took up the position of Professor of Biochemistry at Kings College London, London, UK, carrying out research into the mechanism of the palmitoyl acyltransferases and their role in neurodegenerative disease. H index = 42

Biography Updated on 29 April 2009

Scholarly Contributions [Data Provided by scopus]